Date: 2013-09-12
Type of information:
phase: 2
Announcement: results
Company: Circasssia (UK)
Product: House Dust Mite (HDM)-SPIRE
Action mechanism:
Disease: house dust mite allergy
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country: Canada
Trial details: The trial was conducted in Toronto, Canada, where 172 volunteers with confirmed house dust mite allergy received one of four treatment regimens or placebo. Investigators measured patients\' allergy symptoms when exposed to house dust mite allergens, at the start and during the 12-month study.
Latest
news: * On September 12, 2013, Circassia, a UK specialty biopharmaceutical company focused on allergy, has announced that it has achieved successful results from a phase II clinical study of its house dust mite allergy treatment. Patients who received four doses of the treatment over 12 weeks had significantly improved allergy symptoms one year after the start of the trial compared with placebo, meeting the study\'s long-term primary endpoint. Circassia has submitted the study results for presentation at a leading scientific conference.
